Cicero, Arrigo F. G.

Link to this page

Authority KeyName Variants
031f1b34-4189-44f4-989f-eefb60720287
  • Cicero, Arrigo F. G. (1)
Projects

Author's Bibliography

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL

Vekić, Jelena; Zeljković, Aleksandra; Cicero, Arrigo F. G.; Janez, Andrej; Stoian, Anca Pantea; Sonmez, Alper; Rizzo, Manfredi

(MDPI, 2022)

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Cicero, Arrigo F. G.
AU  - Janez, Andrej
AU  - Stoian, Anca Pantea
AU  - Sonmez, Alper
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4063
AB  - Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.
PB  - MDPI
T2  - Medicina
T1  - Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL
VL  - 58
IS  - 2
SP  - 299
DO  - 10.3390/medicina58020299
ER  - 
@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Cicero, Arrigo F. G. and Janez, Andrej and Stoian, Anca Pantea and Sonmez, Alper and Rizzo, Manfredi",
year = "2022",
abstract = "Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.",
publisher = "MDPI",
journal = "Medicina",
title = "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL",
volume = "58",
number = "2",
pages = "299",
doi = "10.3390/medicina58020299"
}
Vekić, J., Zeljković, A., Cicero, A. F. G., Janez, A., Stoian, A. P., Sonmez, A.,& Rizzo, M.. (2022). Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina
MDPI., 58(2), 299.
https://doi.org/10.3390/medicina58020299
Vekić J, Zeljković A, Cicero AFG, Janez A, Stoian AP, Sonmez A, Rizzo M. Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina. 2022;58(2):299.
doi:10.3390/medicina58020299 .
Vekić, Jelena, Zeljković, Aleksandra, Cicero, Arrigo F. G., Janez, Andrej, Stoian, Anca Pantea, Sonmez, Alper, Rizzo, Manfredi, "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL" in Medicina, 58, no. 2 (2022):299,
https://doi.org/10.3390/medicina58020299 . .
3
36
33